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A B S T R A C T
BACKGROUND: Non alcoholic fatty liver disease (NAFLD) refers to a wide spectrum 
of liver damage, ranging from simple steatosis to steatohepatitis (NASH) and cir-
rhosis. The aim of this study was to describe the variance of clinical and laboratory 
parameters that could play a role in the development of NASH in a group of patients 
with NAFLD.
PATIENTS AND METHODS: Clinical, biochemical and histological features of 36 pa-
tients with NAFLD were analyzed. Insulin and leptin serum levels were measured and 
Body Mass Index (BMI) and insulin resistance (HOMA index) were calculated. The 
same parameters were analyzed in 10 healthy controls.
RESULTS: Signs of chronic liver disease and histological findings of advanced fibrosis 
were detected in 2 patients (5,5%), while hepatomegaly was a frequent finding (21 
patients, 58,3%). NASH was confirmed in 21 patients (58,3%).Statistically significant 
difference was found between patients and controls in BMI (32 vs 25, p=0,002), insu-
lin levels (33,3 vs 9,5, p=0,015) and HOMA index (9,4 vs 2,3 p=0,006). In comparing 
NASH patients with fatty liver (FL) patients, we observed similar levels (31,1 vs 32) of 
BMI, while insulin levels were higher in NASH patients (42 vs 22 p=0,044), as well as 
HOMA (11 vs 7,5) and leptin levels (22 vs 16,6) although this differences did not reach 
a statistical significance.
CONCLUSIONS: This study confirms the important role of obesity and insulin resist-
ance in a group of greek NAFLD patients. A positive correlation is also found be-
tween severity of liver damage and degree of insulin resistance.
I N T R O D U C T I O N
NAFLD is an increasingly recognized condition that refers to a wide spectrum 
of liver damage, ranging from simple fatty liver to steatohepatitis, which can progress 
to advanced fibrosis and cirrhosis. NAFLD should be differentiated from steatosis 
resulting from secondary causes such as genetic disorders (lipodystrophy, dysbetalipo-
proteinemia, etc), nutritional disorders (starvation, total parenteral nutrition, protein 
caloric malnutrition etc), drugs (estrogens, glucocorticoids, amiodarone, valproic acid 
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etc) environmental hepatotoxins, HIv infection, and inflam-
matory bowel disease. (1-6)
NAFLD is mainly associated with obesity, diabetes mellitus 
(type 2), hyperlipidemia and insulin resistance, which are the 
main features of the metabolic syndrome. The pathogenesis of 
NAFLD is poorly understood, as well as why simple steatosis 
develops in some patients, whereas steatohepatitis and progres-
sive disease in others. The “multi-hit” theory suggests that in 
the first “hit”, insulin resistance leads to the accumulation of 
fat within hepatocytes by two main mechanisms: lipolysis and 
hyperinsulinemia. The second “hit” involves oxidative stress 
resulting from mitochondrial release of reactive oxygen spe-
cies, lipid peroxidation, cytokine induction, and the induction 
of Fas ligand. In addition, recent data suggest a potential role 
for leptin - a hormone that regulates body weight through a 
hypothalamic mechanism – in the pathogenesis of NAFLD 
and NASH by inducing dephosphorylation of insulin-receptor 
substrate-1. (3,6-9)
It is also worth noting that, although, NASH was originally 
considered to occur almost exclusively in obese patients, it is 
now known to affect even those with normal body weight.(4,6) 
Furthermore only 10-30% of NAFLD patients have biochemi-
cal and histological findings of NASH an important distinc-
tion since NASH can result in progressive liver disease while 
steatosis alone may not. (6,10)
S T U D Y  A I M
The aim of this study was to measure the prevalence and 
variance of clinical and laboratory parameters in NAFLD 
patients and to detect differences of their levels between NASH 
patients and patients with fatty liver alone, in order to verify 
the association of certain factors – such as the degree of insulin 
resistance, BMI, serum leptin levels – with the development 
of the potentially progressive NASH.
P A T I E N T S  A N D  M E T H O D S
PA T I E N T S
The study was performed in 36 patients, referred to the 
liver unit of our department in the period 2004 to 2006, with 
the following characteristics:
(1) Liver steatosis confirmed by ultrasound. Brightness and 
posterior attenuation were considered indices of the extent 
of fatty infiltration.
(2) Negative or negligible alcohol consumption and no hepa-
totoxic medication.
(3) Negative hepatitis B and C viral markers, absence of au-
toantibodies indicative of autoimmune liver disease, and 
normal ferritin and a1-antithrypsin levels.
The control group included 10 healthy individuals (5 
men and 5 women selected to have the same mean age with 
the patients), with no liver disease history and a normal liver 
ultrasound. They have been submitted in the same, as the 
patients, clinical and laboratory tests.
All the subjects gave informed consent for participation 
in the study.
M E T H O D S
A complete family and personal medical history of all pa-
tients was recorded and a complete physical examination was 
performed. Body weight and height were measured and BMI 
was calculated in all participants. Laboratory studies included 
glucose, creatinine, cholesterol, triglyceride, total bilirubin, 
aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), alkaline phosphatase (ALP), gamma glutamyl trans-
ferase (GGT), albumin and total protein levels; hepatitis B 
surface antigen and antibody to hepatitis C virus; autoim-
mune serology; studies of iron metabolism, ceruloplasmin 
and a1-antitrypsin levels. All the patients underwent a glucose 
tolerance blood test, and insulin and leptin were measured by 
immunoenzymometric assays (Cayman Ch.). Insulin resistance 
was calculated by means of the homeostasis model assessment 
HOMA as follows: HOMA-Index = [fasting insulin (mU/L) 
x fasting glucose (mmol/L)]/22,5.
The patients underwent a liver biopsy, after an informed 
consent was obtained and they were distincted in patients with 
steatohepatitis (NASH) and patients with simple liver steatosis 
(FL), according to Brunt’s histological criteria. (11)
Statistical analysis. All data were analyzed using SPSS, 
and were compared across study groups by use of analysis of 
variance ANOvA.
R E S U L T S
1 .  C H A R A C T E R I S T I C S  O F  PA T I E N T S  A N D 
S E V E R I T Y  O F  L I V E R  D I S E A S E
Demographic and laboratory characteristics of the patients 
are shown in table I. Nine of the patients (25%) were diabetic 
while glucose tolerance test was abnormal in 17 patients (47,2%). 
TABLE Ι. Characteristics of 36 NAFLD patients and healthy 
controls.
Gender (F/M) Mean Age (yr)
NASH* (n=21) 10/11 48,6 (28-73)
FL* (n=15) 8/7 48,5 (36-69)
NAFLD* (n=36) 18/18 48,6 (28-73)
Controls (n=10) 4/6 46,6 (35-58)
* FL: Fatty Liver,  NAFLD: Non-Alcoholic Fatty Liver Disease,   
NASH: Non-Alcoholic Steatohepatitis.
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Biochemical and histological findings of NASH were detected 
in 21 patients (58,3%), the remaining 15 were diagnosed as hav-
ing simple fatty liver (FL). Chronic liver disease stigmata with 
histological findings of advanced fibrosis have been detected 
only in 2 (5,5%), both patients in the NASH group.
2 .  S T A T I S T I C A L  D I F F E R E N C E S  B E T W E E N 
PA T I E N T S  A N D  C O N T R O L S
Comparison of the group of patients with the group of 
healthy controls (Table-II), demonstrated a statistically sig-
nificant difference in:
BMI (32 kg/cm2 in patients, 25 kg/cm2 in controls, 
p=0,002)
Insulin serum levels (33,3 μIU/ml vs 9,5 μIU/ml respec-
tively, p=0,015)
Insulin resistance HOMA (9,4mg/l vs 2,3mg/l, p=0,006)
ALT (mean values 45,2 U/L vs 17,7 U/L, p=0,002)
Serum leptin levels did not differ significantly between 
the two groups.
3 .  S T A T I S T I C A L  D I F F E R E N C E S  B E T W E E N 
N A S H  PA T I E N T S  A N D  PA T I E N T S  W I T H  S I M P L E 
S T E A T O S I S  ( F L )
As shown in Table III, BMI was comparable between the 
group of NASH patients and that with fatty liver (31,1 kg/cm2 vs 
32 kg/cm2 respectively). Insulin serum levels were significantly 
higher in NASH patients (42 μIU/ml vs 22 μIU/ml respectively, 
p=0,04). Serum leptin levels were higher in NASH patients 
(22 ng/ml vs 16,6 ng/ml), as well as insulin resistance HOMA 
index (11 vs 7,5) but the differences were not statistically 
significant. Serum lipid levels did not differ between the two 
groups. Mean values of ALT were higher in NASH patients 
(59,6 vs 25 , p<0,0001).
D I S C U S S I O N
The present report on a group of greek patients, confirms 
that NAFLD is strongly associated with obesity, impaired 
glucose metabolism- hyperinsulinemia and insulin resist-
•
•
•
•
•
ance. These findings agree with those of other studies, and 
confirm the presence of these associations in the greek popu-
lation.(12,13) Since Greece holds one of the highest ranks 
in obesity (women 18,2% - men 26%) among the European 
countries (14), the impact of those morbid conditions in terms 
of public health may be of great importance.
The comparison of NASH patients with those with simple 
steatosis, indicates that the most important risk factor of pro-
gressive liver disease is high insulin levels, indicating insulin 
resistance, a finding in agreement with the results of other 
studies. (8,15,16) We assume that, although HOMA index was 
found higher in NASH patients (10,8 vs 7,5), this difference 
did not reach statistically significant levels because of the rela-
tively small number of patients in each group. BMI and serum 
lipid levels were not found to correlate with the progression of 
liver damage to steatohepatitis in these patients. A possible 
explanation is that although obesity and hyperlipidemia are 
important risk factors of liver steatosis, they do not lead to 
progressive liver damage if insulin resistance does not coexist 
in the same patient.
In this study, although levels of serum leptin were found 
higher in NASH patients (22 ng/ml vs 16,6 ng/ml) they did 
not confirmed a statistically significant difference, as in other 
studies possibly due to the relatively small sample of patients. 
(17-20) However results of recent reports, regarding the role 
of leptin in NAFLD, are controversial (21-23) though in one 
study liver steatosis regressed in patients with severe lipod-
ystrophy. (24)
In conclusion, the results of the present study in a group of 
greek patients, indicate that beyond the well known risk factors 
for NAFLD as obesity and hyperlipidemia – factors important 
for the greek population – insulin resistance holds the major 
role in the progression of the disease to steatohepatitis. The 
probable role of elevated serum leptin levels in promoting liver 
steatosis and NASH needs further investigation.
TABLE ΙΙ. BMI, HOMA, Serum Insulin and leptin levels, 
in patients and controls.
Patients Controls p
BMI 31,44 25,3 0,002
Insulin 33.34 9,5 0,015
HOMA 9,35 2,3 0,006
Leptin 19,7 20 0,95 
ALT 45,2 17,7 0,002
TABLE ΙΙΙ. Clinical and Biochemical markers in NASH 
patients and patients with simple steatosis (FL).
NASH (n=21) FL (n=15) p
BMI 31,1 32 0,62 
Insulin 41,9 21,9  0,044
HOMA 10,8 7,5 0,2 
Leptin 21,9 16,6  0,32 
Triglycerides 153 210 0,2 
Cholesterol 235 231 0,8 
HDL Cholesterol 44,3 44,8 0,9 
ALT 59,6 25 0,0001
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